Back

Elective coronary revascularisation represents an unutilised opportunity to optimise lipid management: results from a multicentre observational cohort

28 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Lipid lowering (1) Drug therapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Miss Manon van den Bogaart

Amsterdam University Medical Centre (AUMC), Amsterdam (Netherlands (The))

6 More presentations in this session

Presentation thumbnail
Bridging the gap: real-world eligibility for lipoprotein(a)-targeted therapies in chronic and acute coronary syndrome
Doctor E. Steinacher (Vienna, AT)
Abstract Slides
Presentation thumbnail
LDL-C target achievement does not equal risk resolution after ACS: residual atherogenic and inflammatory burden despite maximal oral triple lipid therapy
Doctor K. Mahajan (Mandi, IN)
Abstract Slides
Presentation thumbnail
Association of LDL-C/ApoB ratio with pathogenic variants in familial hypercholesterolemia
Doctor F. Wollmann (Wien, AT)
Abstract Slides
Presentation thumbnail
Real-world efficacy and tolerability of lipid-lowering therapy in children with monogenic familial hypercholesterolemia in primary care
Mr R. Schmieder (Munich, DE)
Abstract Slides
Presentation thumbnail
Association of apolipoprotein B and lipoprotein(a) with severe atherosclerotic cardiovascular disease in patients with acute coronary syndrome: the modifying effect of prior lipid-lowering therapy.
Mr A. Meseguer Hernandez (Cartagena, ES)
Abstract Slides

Access the full session

Session thumbnail
Lipid lowering (1)

The Event

Event poster

ESC Congress 2026

28 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
The COR Lipid-Registry: The effectiveness of the strike early and strike strong strategy (SES) in patients with high cardiovascular risk
20 March 2026
thumbnail
Congress Presentation
Determinants of revascularization and outcomes in patients with suspected/known CAD
20 May 2024
thumbnail
Congress Presentation
ACS Program. Improving secondary prevention in patients admitted due to a myocardial infarction. First year experience
25 April 2024
thumbnail
Congress Presentation
Effect and safety of PCSK9 inhibitor in-hospital use on blood lipid level in the ACS patients: a systematic review and meta-analysis
13 April 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources